Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/Mitsubishi Tanabe MS Drug Gets FDA Priority Review

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA granted priority review status to Novartis multiple sclerosis drug Gilenia (oral fingolimod, FTY720). The NDA was accepted by FDA in December and the once-daily Gilenia could become the first approved oral therapy for MS. Licensed from Mitsubishi Tanabe Pharma, the oral fingolimod compound was first developed by Yoshitomi Pharmaceutical (currently Mitsubishi Tanabe), Mitsui Sugar and Kyoto University. (Click here for more - Japanese language

You may also be interested in...



Lannett Reports Insulin Glargine Trial Success

Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.

BREAKING: Sanofi Forms Standalone Consumer Healthcare Unit: Prelude To Spin-Off?

Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business. 

Data Integrity Remains Challenging For API Manufacturers

Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.

UsernamePublicRestriction

Register

SC074244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel